Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases

Jiang,Huifang; Wu,Zhonglin; Ren,Li; Tao,Diehong; Tong,Hongyan

doi:10.3892/ol.2015.3977

Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases

Authors:
- Huifang Jiang
- Zhonglin Wu
- Li Ren
- Diehong Tao
- Hongyan Tong
View Affiliations

Affiliations: Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China, Department of Hematology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China, Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: November 25, 2015 https://doi.org/10.3892/ol.2015.3977
Pages: 689-692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atypical chronic myeloid leukemia (aCML) is a hematopoietic stem/progenitor cell disorder, predominantly involving neutrophils. At present, a limited number of studies regarding the treatment of aCML have been published, and the therapies that are currently available exhibit unsatisfactory outcomes. In the present study, the cases of two aCML patients treated with decitabine (DCA) therapy who achieved remission are presented. A 48‑year‑old male, who presented with fatigue and a cough that had lasted two months, and a 69‑year‑old male who presented with dizziness, fatigue and shortness of breath with exercise, were diagnosed with aCML following bone marrow examination, flow cytometry and chromosome banding analysis. The two patients were treated with four cycles of DCA chemotherapy (20 mg/m2, days 1‑5) and remission was achieved in each patient. The present study evaluated the clinical manifestations, diagnostic criteria and relevant treatment regimens of aCML, which may provide insights for the treatment of affected patients. Routine blood and bone marrow examinations were performed weekly prior to each cycle. Symptoms were relieved in both patients after the first cycle and the two patients were followed up for 3 months after completion of the final cycle. The findings of the current case report indicate that DCA may present an efficacious treatment for aCML.

View Figures

View References

1	Swerdlow SH, Campo E, Harris NL, et al: Atypical chronic myeloid leukaemia, BCR-ABL1 negative. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th). Swerdlow SH and Harris NL: (Lyon, France). IARC Press. 80–81. 2008.
2	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C and Cox C: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 87:746–754. 1994. View Article : Google Scholar : PubMed/NCBI
3	Galton DA: Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk Lymphoma. 7:343–350. 1992. View Article : Google Scholar : PubMed/NCBI
4	Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F and Alimena G: Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 91:1566–1568. 2006.PubMed/NCBI
5	Cannella L, Breccia M, Latagliata R, Frustaci A and Alimena G: Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leuk Res. 32:514–516. 2008. View Article : Google Scholar : PubMed/NCBI
6	Broseus J, Alpermann T, Wulfert M, et al: MPN and MPNr-EuroNet (COST Action BM0902): Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 27:1826–1831. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, et al: Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 123:2645–2651. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S and Mosiman VL: Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy. 11:595–605. 2009. View Article : Google Scholar : PubMed/NCBI
9	Piazza R, Valletta S, Winkelmann N, et al: Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics. 45:18–24. 2013. View Article : Google Scholar : PubMed/NCBI
10	Oscier DG: Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome? Br J Haematol. 92:582–586. 1996. View Article : Google Scholar : PubMed/NCBI
11	Jaffe ES, Harrris NL, Stein H, et al: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classfication of Tumours (Lyon, France). IARC Press. 2001.
12	Hernández JM, del Cañizo MC, Cuneo A, et al: Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 11:441–444. 2000. View Article : Google Scholar : PubMed/NCBI
13	Malcovati L and Cazzola M: Myelodysplastic/myeloproliferative disorders. Haematologica. 93:4–6. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 27:263–270. 2001. View Article : Google Scholar : PubMed/NCBI
15	Montefusco E, Alimena G, Lo Coco F, et al: Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol. 65:17–21. 1992. View Article : Google Scholar : PubMed/NCBI
16	Koldehoff M, Beelen DW, Trenschel R, et al: Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 34:1047–1050. 2004. View Article : Google Scholar : PubMed/NCBI
17	Issa JP and Kantarjian HM: Introduction: emerging role of epigenetic therapy: focus on decitabine. Semin Hematol. 42(3 Suppl 2): S1–S2. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kantarjian H, O'Brien S, Giles F, et al: Decitabine low-dose schedule (100 mg/m²/course) in myelodysplastic syndrome (MDS). Comparison of three different dose schedules. Blood. 106:7082005.
19	Cashen A, Shah A, Helget A, Todt L, Fisher N and DiPersio J: A phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Blood. 106:527–528. 2005.
20	Liu YL, Emanuel PD and Castleberry RP: Decitabine, a potential targeted therapeutic for juvenile myelomonocytic leukemia. Blood. 106:7062005.PubMed/NCBI